IPH Limited (IPH) Buy at the bottom
|
|
- Elwin Henderson
- 5 years ago
- Views:
Transcription
1 29 March 2017 Analyst Sam Haddad Authorisation TS Lim IPH Limited (IPH) Buy at the bottom Recommendation Buy (unchanged) Price $4.76 Target (12 months) $7.90 (unchanged) Expected Return Capital growth 65.9% Dividend yield 5.0% Total expected return 70.9% Company Data & Ratios Enterprise value $857m Market cap $915m Issued capital 192.3m Free float ~82% Avg. daily val. (52wk) $5.6m 12 month price range $ $7.27 GICS sector Price Performance Professional Services (1m) (3m) (12m) Price (A$) Absolute (%) Rel market (%) We believe IPH s share price has bottomed & currently represents an attractive, timely opportunity to Buy. We believe the negative issues are behind and believe a number of positive drivers will emerge that will support the share price, as discussed in this note. We believe the negatives are behind and priced in Key negative factors that have weighed on IPH s share price and now behind include: Share overhang removed, with ~30m of escrowed shares sold. AIA impact behind. Growth in IPH s Asian business was weak in CY16 due to a strong CY15. In CY15, the pull-forward of filings due to AIA saw IPH s Singapore office grow at double the market pace (up ~11% on CY14 vs market at ~5%). Loss of a large client of Callinans/Pizzeys following the acquisition of Callinans. While one-off in nature & not material to IPH, this weighed on investor sentiment. The reallocation of investment funds across three listed IP firms. Delays in securing key acquisitions and the upfront due-diligence costs incurred. and believe a number of positives now lie ahead Key positive factors that we see lie ahead and will be supportive to the share price are: The resumption of solid growth in IPH Asia. We are forecasting high single-digit organic growth in 2HFY17 as the comparable period normalises post AIA. We see potential upside risk to IPH s FY17 EBITDA $72m-$74m guidance range, with the resumption of growth in Asia the key swing factor (as per Figure 2). Integration/other synergies yet to be realised. While integration is well underway, no material cost-out benefit has to date been realised. We expect this to begin to flow in 2HFY18/FY19, although have not yet allowed for this in our forecasts. The previously flagged key acquisition prospect in Asia remains active. Timing on this remains difficult to assess, although a resolution by end-cy17 is possible. Earnings changes & Investment view Retain Buy, PT $7.90 There is no material change to our forecasts & our PT is unchanged at $7.90. IPH is a high quality business across many facets. We believe IPH s derating s well overdone and believe a number of positives will emerge that will support a recovery. Buy rating. Absolute Price $10.0 $9.0 $8.0 $7.0 $6.0 $5.0 $4.0 $3.0 $2.0 $1.0 Mar Jul 15 Nov IPH Mar 16 SOURCE: IRESS BELL POTTER SECURITIES LIMITED ACN AFSL Jul 16 Nov 16 S&P 300 Rebased Earnings Forecast Jun Year end 2016a 2017e 2018e 2019e Sales (A$m) EBITDA (A$m) NPAT (reported) (A$m) NPAT (underlying) (A$m) EPS underlying (cps) EPS underlying growth (%) 34.0% 7.2% 12.3% 10.2% PER (on underlying EPS) (x) EV/EBITDA (x) Dividend ( ps) Yield (%) 4.4% 5.0% 5.6% 6.2% Franking (%) 65% 74% 65% 65% SOURCE: BELL POTTER SECURITIES ESTIMATES DISCLAIMER AND DISCLOSURES THIS REPORT MUST BE READ WITH THE DISCLAIMER AND DISCLOSURES ON PAGE 7 THAT FORM PART OF IT. Page 1
2 Mar-14 Jun-14 Sep-14 Dec-14 Mar-15 Jun-15 Sep-15 Dec-15 Mar-16 Jun-16 Sep-16 Dec-16 Mar-17 Negatives behind, positives lie ahead IPH has experienced a significant PE derating Since June 2016, IPH (along with its peers) has experienced a material derating in PE ratio valuation from what was a comfortable premium vs the market (defined by the published Bloomberg PE for the ASX 200/All Ordinaries indices), to now at around par. Figure 1 illustrates IPH s rolling 1-year forward consensus PE over time. Figure 1 PE valuation for IPH & other IP Groups vs market PE (first year forward estimates) IPH QIP XIP ASX 200 All Ordinaries Index SOURCE: BLOOMBERG As detailed in our sector note dated 14 March 2017, we attributed the de-rating in IPH and, more broadly, the IP sector, to the following factors: The market discovering the fair value for a new ASX sector that has no offshore listed equivalent; This path of discovery initially shifted the sector (which initially only included IPH) to stretched valuation levels, justifying a de-rating at that time off these highs. Note that we downgraded our rating on IPH from Buy to Hold in Feb 2016 on valuation grounds. We have since reinstated our Buy rating following a ~30% retreat in IPH s share price; The re-allocation of investment funds from initially just IPH to two IP groups (once XIP listed) and now three IP groups (once QIP listed); A slowdown in EPS growth rate, primarily for IPH, on the back of reducing accretive/ arbitrage benefits from acquisitions (off a growing base), the reduction in FX tailwinds, as well as IPH s slower growth rate in Asia throughout CY16 while cycling impacts of the America Invests Act (AIA); The loss of a large client of Callinans/Pizzeys following IPH s acquisition of Callinans. While one-off in nature and not material to IPH, this did weigh on investor sentiment; The overhang of IPH shares in the lead-up to escrow period expiry in Nov 2016; and Delays in securing key acquisitions and the upfront due-diligence costs incurred. We believe the negatives are behind and believe a number of positives now lie ahead that will support IPH s share price We believe the negatives in the stock are behind and believe a number of positive drivers will emerge that will support the share price, as follows: Share overhang removed, with ~30m of escrowed shares sold. IPH management s shareholding has reduced from almost 40% to ~18%, increasing market liquidity. Page 2
3 The impact of AIA is behind. Growth in IPH s Asian business was weak in CY16 due to a strong CY15. In CY15, the pull-forward of filings due to AIA saw IPH s Singapore office grow at double the market pace (up ~11% on CY14 vs market at ~5%). We are forecasting a resumption of solid growth (high single-digit growth) in 2HFY17 as the comparable period normalises post AIA. We see potential upside risk to IPH s FY17 EBITDA $72m-$74m guidance range, with the resumption of growth in Asia the key swing factor, as illustrated in Figure 2. Figure 2 EBITDA bridge analysis FY16 to FY17 (BPe and assuming FX has no material impact) $M Negative growth in 1H17 partially offset by an expected improved result in 2H17. We believe there is scope for this to surprise on the upside. BPe is $73.9m (top end of IPH's guidance range) Company FY17 EBITDA guidance range is $72m to $74m FY16 EBITDA S&F ANZ growth FAKC + full New earnings New earnings, period Pizzeys from Cullens Ella Cheong S&F Asia growth Data Services Investment Increased corporate costs FY17e EBITDA, BPe SOURCE: BELL POTTER SECURITIES ESTIMATES Integration synergies & other cost efficiencies are yet to be realised. While integration is well underway, no material cost-out benefit has to date been realised. We expect this to begin to flow in 2HFY18/FY19, although have not yet allowed for this in our forecasts. The previously flagged key acquisition prospect in Asia remains active. Timing on this remains difficult to assess, although a resolution by end-cy17 is possible. We believe IPH is well oversold, valuation premium is justified Figure 3 shows a snapshot of IPH s current valuation vs peers/market (i.e. the exiting data points in the earlier Figure 1 correspond with the FY17 PE ratios tabulated in Figure 3). Figure 3 PE ratios and EV/EBITDA multiples for IPH vs its peers and market Peer EV P/E 1 EV/EBITDA EPS Growth (%) 1 Div Yield (%) (A$m) FY16 FY17e FY18e FY19e FY16 FY17e FY18e FY19e FY16 FY17e FY18e FY19e FY16 FY17e FY18e FY19e IPH Limited (IPH) % 7.7% 11.8% 9.9% 4.4% 4.9% 5.5% 6.1% IPH premium/discount to average 20% 20% 20% 21% 21% 21% IPH premium/discount to ASX 200 index 5% -3% -7% QANTM IP Limited (QIP) % 11.9% 9.3% 4.7% 6.4% 6.9% QIP premium/discount to average -5% -1% -1% 0% -1% 0% QIP premium/discount to ASX 200 index -13% -19% -22% Xenith IP Group Limited (XIP) % 13.4% 12.8% 3.0% 4.0% 6.5% 7.6% XIP premium/discount to average -16% -19% -19% -21% -20% -21% XIP premium/discount to ASX 200 index -29% -35% -39% Average % 12.3% 10.7% 4.5% 6.1% 6.9% ASX 200 Index IP sector ave. premium/discount to ASX % -19% -23% 1 Price earnings ratio on NPATA (x); and EPS growth on NPATA (%) 2 QIP FY17e Divident Yield is based on pariod from 30 August 2016 to 30 June 2017 (and therefore is not an annualised yield). SOURCE: SOURCE: COMPANY DATA AND BLOOMBERG CONSENSUS ESTIMATES As illustrated, based on Bloomberg consensus forecasts, IPH is currently trading at roughly par with market. As detailed in our sector note dated 14 March 2017, we believe the IP sector average PE should trade at a premium to the market PE. In addition, we believe it s justified for IPH to trade at a premium to QIP and XIP given IPH s greater scale and Page 3
4 geographic coverage including market leadership positions in Singapore and ANZ and an established presence in key SEA markets that is now broadening into inbound Greater China. This in turn provides automatic scale and leverage exposure to the high growth Asian market (~40% of IPH s earnings) including more immediate scope for market share gains across multiple Asian markets. Page 4
5 IPH Limited Company Description IPH Limited (IPH) wholly owns Spruson & Ferguson, Pizzeys, Fisher Adams Kelly Callinans, Cullens & Practice Insight. IPH is the leading Intellectual Protection (IP) services group in the Asia-Pacific region employing ~475 staff, with specialist services spanning the protection, commercialisation, enforcement and management of most types of IP. Key practice areas include: Patents & Designs (Patent work being IPH s major rev contributor); Trade Marks, Domain & Business Names ; & Legal (commercial legal advice/ip litigation). Investment Strategy We rate IPH Buy with a price target of $7.90. IPH is strategically positioned as the leading one-stop gateway for Asia-Pacific. In Asia we view IPH s growth prospects as two-fold: 1) growth of the market itself; and 2) market share gains. As the number one IP firm in Singapore, IPH is well placed to leverage off Singapore s emerging role as the IP hub of Asia. We believe this, plus the opportunity to leverage off its clients, positions IPH on strong footing to take share. In Australia, while mature, the market is fragmented. We believe IPH is in solid position to acquire. There is also opportunity for IPH to expand into target secondary markets beyond the Asia-Pacific region and ultimately become the global firm for secondary markets. This long-term vision is embedded in IPH s mission statement. Valuation Our 12 month valuation is $7.90 based on DCF. Major assumptions are a WACC of 10% & a terminal growth rate of 4%. We also include a 10% high acquisition propensity premium. Risk to Investment Thesis Key downside risks to our valuation include (but are not limited to): Regulatory reform risk: Amendments to current legislation or the introduction of new legislation may cause material changes in patent or trademark flow volumes. Competition risk: This will impact margins and may impinge on IPH s market share Foreign exchange risk: IPH is exposed to both transactional & translational currency risk and does not hedge against this. Any adverse FX movements or volatility (esp, vs the $A) could have an adverse effect on IPH s financial performance and position. Acquisition risks: Poor due diligence or unsuccessful integration will impact earnings. Macro-economic risks: Adverse economic conditions may cause IPH s clients to defer /cancel IP spend or exert pricing pressure. Activity levels in key industry sectors: IPH s client base is spread across numerous sectors. Adverse developments in key sectors may impact demand for IPH s services. Personnel: The departure of any key personnel would likely have an adverse effect. Brand and reputation risks: Anything that diminishes IPH s reputation or brand would likely impact the level of enquiries, which in turn may reduce profitability and growth. Concentration of shareholding: Key shareholders can exert significant influence on company matters. Concentration may impact market liquidity / create stock overhang. Patent filing management and IT systems: Any interruption, loss or delay of IPH s IT facilities/tools, or loss of data/records, may impact IPH financially & with client relations. Page 5
6 IPH Limited as at 29 March 2017 Recommendation Buy Price $4.76 Target (12 months) $7.90 Table 1 - Financial summary Jun Year end e 2018e 2019e Price $4.76 Profit & Loss (A$m) Recommendation Buy Sales revenue Diluted issued capital (m) Change 19.4% 51.3% 34.8% 11.1% 6.6% Market cap ($m) EBITDA Target Price (A$ps) $ Change 41.0% 53.7% 13.7% 12.7% 9.5% Deprec. & amort. (1.1) (2.2) (1.9) (3.1) (3.6) Jun Year end e 2018e 2019e EBIT Valuation Ratios Net Interest (0.6) (1.0) (0.3) Underlying EPS ( ps) Pre-tax profit % change 40.9% 34.0% 7.2% 12.3% 10.2% Tax expense (9.7) (14.9) (17.9) (20.0) (21.8) PE (on underlying EPS) (x) tax rate 24% 24% 25% 25% 25% EV/EBITDA (x) Associates EV/EBIT (x) Minorities/Prefs Underlying Net Profit NTA ($ps) Change 41.3% 51.6% 14.8% 12.8% 10.2% P/NTA (x) 1, Abs. & extras. - (8.1) (4.5) - - Book Value ($ps) Reported Profit Price/Book (x) Cashflow (A$m) DPS ( ps) EBITDA % pay-out 70.5% 84.0% 84.2% 84.8% 85.0% Working capital changes (3.6) (6.6) (7.4) (3.9) (2.3) Yield (%) 2.8% 4.4% 5.0% 5.6% 6.2% Net Interest Expense (0.5) (1.0) (0.3) Franking (%) 65% 65% 74% 65% 65% Tax (4.8) (13.1) (15.1) (19.1) (20.9) Other operating items (1.8) (2.2) (1.1) (5.8) 0.1 Performance Ratios Operating Cash Flow Revenue growth (%) 19.4% 51.3% 34.8% 11.1% 6.6% Capex (0.6) (2.6) (2.4) (3.4) (3.7) EBITDA growth (%) 41.0% 53.7% 13.7% 12.7% 9.5% Free Cash Flow EBITDA/sales margin (%) 44.7% 45.4% 38.3% 38.9% 39.9% Acquisitions (3.9) (49.6) (31.7) - - EBIT/sales margin (%) 43.6% 43.9% 37.3% 37.4% 38.3% Disposals Dividends paid (26.8) (33.8) (40.9) (48.5) (54.4) Gross cash conversion (%) 87.2% 86.4% 88.4% 88.3% 97.6% Other investing items 0.1 (0.7) Free cash-flow yield (%) 4.1% 4.6% 5.2% 5.6% 7.2% Equity ROE (%) n/a n/a 22.9% 24.1% 25.2% Debt increase/(reductio 1.0 (10.6) (1.8) (3.1) (11.2) ROIC (%) 156.6% 44.1% 28.8% 28.6% 30.7% Capex/Depn (x) Balance Sheet (A$m) Cash Net interest cover (x) n/a n/a Receivables Net Debt/EBITDA (x) 0.1 n/a n/a n/a n/a Inventories & WIP Net debt/equity (%) 14.8% -26.5% -13.9% -14.3% -17.8% Other current assets Net debt/net debt + equity (%) 12.9% -36.0% -16.1% -16.8% -21.6% Current Assets Receivables Segmental Information Assoc & investments Fixed Assets Australia and New Zealand Intangibles Asia Other non-curr assets Other/Adj. (2.5) (4.5) (5.0) (5.4) (5.9) Non Current Assets Total Revenue (A$m) Total Assets Short term debt Australia and New Zealand Creditors Asia Provisions Corp/Elimin/Other - (4.2) (9.1) (7.5) (5.8) Other curr liabilities Total EBITDA (A$m) Current Liabilities Long term debt Half yearly (A$m) 2H15 1H16 2H16 1H17 2H17e Creditors Sales revenue Provisions EBITDA Other non curr liabilities Deprec. & amort. (0.6) (0.8) (1.4) (0.7) (1.2) Non Current Liabilities EBIT Total Liabilities Interest expense (0.4) (0.9) (0.1) (0.5) 0.2 Net Assets Pre-tax profit Share Capital Tax expense (5.5) (7.0) (7.9) (8.6) (9.3) Reserves (14.6) (13.2) (12.7) (12.7) (12.7)... tax rate 24% 23% 25% 24% 25% Retained Earnings Associates Shareholders Equity Minorities Outside Equity Interests Underlying Net Profit Total Equity Abs. & extras. - (4.9) (3.2) (4.5) - Reported Profit Net debt/(cash) $m 5.2 (58.8) (34.0) (37.1) (48.3) SOURCE: BELL POTTER SECURITIES ESTIMATES Page 6
7 Recommendation structure Buy: Expect >15% total return on a 12 month view. For stocks regarded as Speculative a return of >30% is expected. Research Team Staff Member TS Lim Sam Haddad Jonathon Higgins Title/Sector Head of Research Phone tslim shaddad jhiggins Hold: Expect total return between -5% Chris Savage csavage and 15% on a 12 month view Jonathan Snape jsnape Sell: Expect <-5% total return on a 12 month view John Hester Tanushree Jain Financials Healthcare Healthcare/Biotech jhester tnjain Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet. TS Lim Lafitani Sotiriou Resources Peter Arden David Coates Associates Hamish Murray Tim Piper Banks/Regionals Diversified Resources Resources Associate Analyst Associate Analyst tslim lsotiriou parden dcoates hmurray tpiper Such investments may carry an exceptionally high level of capital risk and volatility of returns. Bell Potter Securities Limited ACN Level 38, Aurora Place 88 Phillip Street, Sydney 2000 Telephone The following may affect your legal rights. Important Disclaimer: This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. In Hong Kong this research is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. This is general investment advice only and does not constitute personal advice to any person. Because this document has been prepared without consideration of any specific client s financial situation, particular needs and investment objectives ( relevant personal circumstances ), a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arraignment with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this document. While this document is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in the document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views opinions, or recommendations contained in this document or for correcting any error or omission which may become apparent after the document has been issued. Except insofar as liability under any statute cannot be excluded. Bell Potter Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person. Disclosure of interest: Bell Potter Securities Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document. ANALYST CERTIFICATION Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report. Page 7
Platinum Asset Management (PTM)
24 February 2017 Analyst Lafitani Sotiriou 613 9235 1668 Associate Analyst James Filius 613 9235 1612 Authorisation TS Lim 612 8224 2810 Recommendation Hold (unchanged) Price $5.10 Target (12 months) $4.90
More informationPerpetual (PPT) Oversold, upgrade to Buy. Over 6% yield, with upside in market rally. Quarterly highlights. Earnings revisions
16 April 2018 Analyst Lafitani Sotiriou 613 9235 1668 Authorisation TS Lim 612 8224 2810 Perpetual (PPT) Oversold, upgrade to Buy Recommendation Buy (Hold) Price $42.09 Target (12 months) $47.50 (previously
More informationBWX Limited (BWX) SOURCE: BELL POTTER SECURITIES ESTIMATES
9 February 2017 Analyst John O'Shea 613 9235 1633 Authorisation John Hester 612 8224 2871 Recommendation Buy (unchanged) Price $4.80 Target (12 months) $5.73 (unchanged) Expected Return Capital growth
More informationAdacel Technologies (ADA)
9 November 2018 Chris Savage 612 8224 2835 Authorisation TS Lim 612 8224 2810 Adacel Technologies (ADA) Bad, but not that bad Recommendation Buy (unchanged) Price $0.88 Target (12 months) $1.50 (previously
More informationOneVue Holdings (OVH)
24 April 2018 Analyst Lafitani Sotiriou 613 9235 1668 Authorisation Peter Arden 613 9235 1833 OneVue Holdings (OVH) Restructured and focused Recommendation Buy (unchanged) Price $0.745 Target (12 months)
More informationOneVue Holdings (OVH)
7 August 2017 Analyst Lafitani Sotiriou 613 9235 1668 Associate Analyst James Filius 613 9235 1612 Authorisation TS Lim 612 8224 2810 OneVue Holdings (OVH) FY17 result to show cost-out progress Recommendation
More informationNanosonics (NAN) Preparing for new international markets. Maintain Hold, price target amended to $3.20 SOURCE: BELL POTTER SECURITIES ESTIMATES
21 February 2017 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Nanosonics (NAN) Growth Slowly Emerging In Europe Recommendation Hold (unchanged) Price $2.80 Target (12 months) $3.20
More informationSurfStitch (SRF) Shaping the Surf industry. Acquisition in Product drives credibility. however we have some concerns
26 November 20 Analyst Sam Byrnes 612 8224 2886 Authorisation Chris Savage 612 8224 2835 SurfStitch (SRF) Shaping the Surf industry Recommendation Buy (unchanged) Price $2.06 Target (12 months) $2.65 (previously
More informationMayne Pharma (MYX) Yet Another Transformational Acquisition. FY16 Earnings Confirmed. The company did not provide guidance in respect of FY17.
29 June 2016 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Mayne Pharma (MYX) Merger Fallout Creates Opportunity Recommendation Buy (unchanged) Price $1.485 Target (12 months) $1.89
More informationOsprey (OSP) FY16 EBITDA Loss In Line. OSP has US$21.8m of cash as at 31 December Maintain Buy Rating And Valuation at $0.55
27 February 2017 Analyst John Hester 612 8224 2871 Authorisation Tanushree Jain 612 8224 2849 Recommendation Buy (unchanged) Price $0.415 Valuation $0.55 (unchanged) Risk Speculative GICS Sector Healthcare
More informationPremier Investments (PMV)
16 March 2018 Analyst Sam Haddad 612 8224 2819 Authorisation Tim Piper 612 8224 2825 Premier Investments (PMV) Key growth pillars all strong Recommendation Buy (unchanged) Price $15.27 Target (12 months)
More informationNanosonics (NAN) Summary of 2Q17 Cash Flows SOURCE: BELL POTTER SECURITIES ESTIMATES
16 January 2017 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Nanosonics (NAN) US Market Continues To Expand Recommendation Hold (unchanged) Price $3.16 Target (12 months) $3.28
More informationChallenger (CGF) Expanding the potential. A broader and more robust business emerging. Earnings revisions SOURCE: BELL POTTER SECURITIES ESTIMATES
14 February 2017 Analyst Lafitani Sotiriou 613 9235 1668 Associate Analyst James Filius 613 9235 1612 Authorisation TS Lim 612 8224 2810 Challenger (CGF) Expanding the potential Recommendation Buy (unchanged)
More informationANZ Bank (ANZ) Unquestionably strong 1Q17. Healthy Jaws, safe to go back in the water SOURCE: BELL POTTER SECURITIES ESTIMATES
17 February 2017 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 ANZ Bank (ANZ) Unquestionably strong 1Q17 Recommendation Buy (Hold) Price $30.21 Target (12 months) $33.25 (previously
More informationFortescue Metals Group Ltd (FMG)
3 March 2017 Analyst David Coates 612 8224 2887 Authorisation Peter Arden 613 9235 1833 Fortescue Metals Group Ltd (FMG) All about the iron ore price Recommendation Sell (unchanged) Price $6.62 Target
More informationCyclopharm (CYC) Entry to US market inching closer. Maintain Buy Recommendation SOURCE: BELL POTTER SECURITIES ESTIMATES
Analyst John Hester 612 8224 2871 Cyclopharm (CYC) 5 March 2018 Speculative See key risks on Page 4 and Biotechnology Risk Warning on Page 7. Speculative securities may not be suitable for Retail Clients.
More informationANZ Banking Group (ANZ)
1 May 2018 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $27.47 Target (12 months) $30.20 (unchanged) GICS Sector Banks Expected Return Capital
More informationPremier Investments (PMV)
4 April 2017 Analyst Sam Haddad 612 8224 2819 Authorisation TS Lim 612 8224 2810 Premier Investments (PMV) The Myers touch Recommendation Buy (unchanged) Price $14.20 Target (12 months) $17.65 (previously
More informationAeon Metals Limited (AML)
Analyst David Coates 612 8224 2887 Authorisation Stuart Howe 613 9235 1856 Speculative See key risks on Page 4 Speculative securities may not be suitable for retail clients 22 March 2019 Aeon Metals Limited
More informationAuswide Bank (ABA) There are no tricks in plain and simple faith. 24 August : Underlying NPAT $17m, final dividend 18cps
24 August 2018 TS Lim 612 8224 2810 Authorisation Tim Piper 612 8224 2825 Recommendation Buy (unchanged) Price $5.71 Target (12 months) $6.20 (previously $5.80) GICS Sector Banks Expected Return Capital
More informationNational Australia Bank (NAB)
6 February 2017 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $30.39 Target (12 months) $32.50 (previously $30.00) Expected Return Capital growth
More informationCommonwealth Bank (CBA)
10 February 2016 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Commonwealth Bank (CBA) Ordeal and triumph Recommendation Buy (unchanged) Price $74.20 Target (12 months) $83.50 (previously
More informationWestgold Resources (WGX)
3 September 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $1.36 Target (12 months) $2.15 (unchanged) Expected Return Capital growth
More informationOsprey Medical (OSP)
18 October 2017 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Osprey Medical (OSP) Harvey and Irma Curtail Growth Speculative See key risks on Page 5 and Biotechnology Risk Warning
More informationNational Australia Bank (NAB)
29 March 2016 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $25.62 Target (12 months) $29.50 (unchanged) Expected Return Capital growth 15.1%
More informationMetals X Limited (MLX)
16 July 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.655 Target (12 months) $0.95 (previously $0.98) Expected Return Capital growth
More informationMetals X Limited (MLX)
5 September 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.515 Target (12 months) $0.90 (previously $0.95) Expected Return Capital
More informationPeet Bonds (PPCHA) A yield uplift from fixed rate senior debt
4 May 2016 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 (PPCHA) Authorisation TS Lim 612 8224 2810 Fixed Income Issue overview Issuer Issue ASX code Peet PPCHA Face value $100 Estimated
More informationTech Sector. Updated key sells: None. Company Ticker Share price at Market Year end 22-Mar-17 cap FY17a/CY17e FY18e/CY18e FY17a/CY17e FY18e/CY18e
22 March 2017 Analyst Chris Savage 612 8224 2835 Authorisation TS Lim 612 8224 2810 Tech Sector Key picks unchanged: IRI, APX, ADA & IFM Stock Price Target Rating ADA $2.37 $3.25 Buy ALU $7.41 $7.90 Hold
More informationMetals X Limited (MLX)
19 April 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.76 Target (12 months) $0.98 (previously $1.00) Expected Return Capital growth
More informationBUY SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS
BUY 0.11 0.39 0.69 SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS CONTENTS Competitors Products Sales channels Pricing Model INVESTMENT THESIS COMPANY OVERVIEW INDUSTRY OVERVIEW COMPETITORS BOARD
More informationFor personal use only
ASX Announcement 11 October 2017 Presentation by Andrew Blattman & John Wadley to the Morgans Queensland Conference Attached is a presentation to be given this afternoon by Spruson & Ferguson s CEO, Dr
More informationPioneer Credit (PNC)
23 June 2014 Analyst Sam Byrnes 612 8224 2886 Authorisation Chris Savage 612 8224 2835 Pioneer Credit (PNC) Helping not chasing Recommendation Buy (Initiation) Price $1.55 Target (12 months) $1.80 Expected
More informationMesoblast (MSB) GVHD granted Fast Track, should benefit ongoing negotiations with Mallinckrodt
7 March 2017 Analyst Tanushree Jain 612 8224 2849 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $1.90 Valuation $3.22 (previously $3.17) Risk Speculative GICS Sector Pharmaceuticals
More informationBreaker Resources NL (BRB)
David Coates 612 8224 2887 Authorisation Peter Arden 613 9235 1833 Speculative See key risks on Page 6. Speculative securities may not be suitable for retail clients 8 February 2019 Breaker NL (BRB) More
More informationFortescue Metals Group (FMG)
30 October 2015 Analyst David Coates 612 8224 2887 Authorisation John Hester 612 8224 2871 Recommendation Buy (Hold) Price $2.09 Target (12 months) $2.40 (unchanged) Expected Return Capital growth 14.8%
More informationGalaxy Resources Ltd (GXY)
Analyst Peter Arden 613 9235 1833 Authorisation Duncan Hughes 618 9326 7667 Recommendation Buy (unchanged) Price $1.835 Valuation $3.35 (unchanged) -------------- Risk Speculative Expected Return Capital
More informationGalaxy Resources Ltd (GXY)
27 March 2018 Analyst Peter Arden 613 9235 1833 Authorisation Duncan Hughes 618 9326 7667 Galaxy Resources Ltd (GXY) Mt Cattlin doing what it is meant to Recommendation Buy Price $3.16 Price Target $4.75
More informationUBS Investment Research Brambles Limited
UBS Investment Research Brambles Limited FY12 result: strong revenue momentum Result highlights strong revenue momentum Brambles FY12 result was slightly ahead of expectations, revealing 11% underlying
More information7.0% fully franked yield (expected 10.0% gross): Fixed until Nov 2018 reset date
6 July 2012 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 William Spraggett 613 9235 1733 Whitefield Resettable Preference Shares (WHFPB) Authorisation John Gleeson 612 9255 7220
More informationWestgold Resources (WGX)
7 February 2017 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $2.25 Target (12 months) $2.60 Expected Return Capital growth 15.6% Dividend
More informationParagon Care (PGC) Big Boxes, Big Opportunity. Capitalising on the burgeoning healthcare sector. Price leadership through quality
26 September 2014 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Paragon Care (PGC) Big Boxes, Big Opportunity Recommendation Buy (Initiation) Price $0.33 Target (12 months) $0.38
More informationTalisman Mining Ltd (TLM)
Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.41 Valuation $0.88 (previously $1.00) Risk Speculative Expected Return Capital growth
More informationASX Announcement. 16 November AGM Presentations
ASX Announcement 16 November 2016 AGM Presentations In accordance with the ASX Listing Rules and the Corporations Act 2001, attached are the presentations to be given at today s Annual General Meeting.
More informationMetals X Limited (MLX)
1 November 2016 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $1.38 Target (12 months) $2.10 (unchanged) Expected Return Capital growth
More informationFull Year Results Presentation
Full Year Results Presentation Year ended 30 June 2016 David Griffith - Managing Director, IPH Limited Dr. Andrew Blattman - CEO, Spruson & Ferguson Malcolm Mitchell - Group Chief Financial Officer, IPH
More informationFor personal use only
HY17 Results Presentation Half Year Ended 31 December 2016 David Griffith - Managing Director, IPH Limited Dr. Andrew Blattman - CEO, Spruson & Ferguson John Wadley - Chief Financial Officer, IPH Limited
More informationConsolidated Operations Group (COG)
Consolidated Operations Group (COG) 10 April 2018 Outperform Upgrade to OUTPERFORM - Inflection point nearing $0.10 Jason Palmer jpalmer@taylorcollison.com.au +618 8217 3965 Summary (AUD) Market Capitalisation
More informationPresentation by Andrew Blattman to Goldman Sachs Small & Mid-Cap Conference
ASX Announcement 18 April 2018 Presentation by Andrew Blattman to Goldman Sachs Small & Mid-Cap Conference Attached is a presentation to be given today by IPH s CEO & Managing Director, Andrew Blattman,
More information2018 HALF YEAR RESULTS INVESTOR PRESENTATION
2018 HALF YEAR RESULTS INVESTOR PRESENTATION Half Year Ended 31 December 2017 Dr. Andrew Blattman Managing Director / CEO, IPH Limited John Wadley Chief Financial Officer, IPH Limited Disclaimer This document
More informationBreaker Resources NL (BRB)
Analyst David Coates 612 8224 2887 Authorisation Peter Arden 613 9235 1833 Recommendation Buy (unchanged) Price $0.315 Valuation $0.96 (previously $1.30) Risk Speculative GICS Sector Materials Expected
More information2018 Full Year Results Investor Presentation
2018 Full Year Results Investor Presentation Year ended 30 th June 2018 16 th August 2018 Presented by: Dr. Andrew Blattman Managing Director / CEO, IPH Limited John Wadley Chief Financial Officer, IPH
More informationPresentation by Andrew Blattman to the Macquarie Australia Conference
ASX Announcement 1 May 2018 Presentation by Andrew Blattman to the Macquarie Australia Conference Attached is a presentation to be given today by IPH s CEO & Managing Director, Andrew Blattman, to the
More informationResetting expectations
Company update 13 May 2016 TPI ENTERPRISES (TPE) Resetting expectations We retain a BUY rating with a revised 12-month price target of $3.21 p/sh. We assess market conditions to imply a more gradual ramp
More informationSt George Mining Ltd (SGQ)
Analyst Peter Arden 613 9235 1833 Authorisation Duncan Hughes 618 9326 7667 Recommendation Buy (unchanged) Price $0.225 Valuation $0.30 (previously $0.26) Risk Speculative Expected Return Capital growth
More informationPresentation by Dr Andrew Blattman to the Goldman Sachs Emerging Leaders Conference 2019
ASX Announcement 4 April 2019 Presentation by Dr Andrew Blattman to the Goldman Sachs Emerging Leaders Conference 2019 Attached is a presentation to be given today by IPH s CEO & Managing Director, Dr
More informationBoart Longyear. Earnings and target price revision. No change. Price catalyst. Action and recommendation
AUSTRALIA BLY AU Price (at 08:01, 12 Sep 2013 GMT) Neutral A$0.50 Valuation A$ 0.71 - DCF (WACC 10.1%, beta 1.5, ERP 0.1%, RFR 0.1%, TGR 0.0%) 12-month target A$ 0.56 12-month TSR % +12.0 Volatility Index
More informationValue at the top end. Figure 1: Trading margins on debt and equity securities
17 February 2012 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation Steve Goldberg 612 8224 2809 Westpac Convertible Preference Shares (WBCPC) Fixed Interest Issue overview
More informationNoni B (NBL) SFH acquisition could be up to 60% EPS accretive. Key points. Risks and catalysts
Date Theme Company Update Company Noni B (NBL) SFH acquisition could be up to 6 EPS accretive Press reports today (Australian) suggest Noni B is a potential acquirer of Specialty Fashion Group (SFH), in
More informationAsset revaluation driven by almonds
Company update 20 July 2015 RURAL FUNDS GROUP (RFF) Asset revaluation driven by almonds We retain a BUY rating with a 12-month target of $1.15 p/unit. RFF is a listed property trust with a portfolio of
More informationStrike Energy Ltd (STX)
Analyst Peter Arden 613 9235 1833 Authorisation Stuart Howe 613 9235 1782 Recommendation Buy (unchanged) Price $0.115 Valuation $0.26 (previously $0.23) Risk Speculative Expected Return Capital growth
More informationRide the recovery. Figure 1: Trading margins on debt and equity securities. (prior to exchange) over BBSW Mand Conv* Call
17 May 2016 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation TS Lim 612 8224 2810 Fixed Income Issue overview Issuer Issue ASX code BELL POTTER SECURITIES LIMITED ACN
More informationSG Fleet Group. Another UK acquisition. Earnings and target price revision
AUSTRALIA SGF AU Price (at 08:26, 30 Nov 2016 GMT) Outperform A$3.23 Valuation - PER A$ 3.96-4.22 12-month target A$ 4.37 12-month TSR % +41.0 Volatility Index High GICS sector Commercial & Professional
More informationMacquarie Group Capital Notes 2 (MQGPB) * MANDATORY CONVERSION IS SUBJECT TO SATISFYING THE MANDATORY CONVERSION CONDITIONS
23 November 2015 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation Macquarie Group Capital Notes 2 (MQGPB) TS Lim 612 8224 2810 Fixed Interest Issue overview Issuer Issue
More informationMEDICAL DEVELOPMENTS INTERNATIONAL LTD
MEDICAL DEVELOPMENTS INTERNATIONAL LTD No pain in Germany HOLD Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals 6 April 2018 COMPANY UPDATE Ticker MVP Stock Price $7.10 Target Price $8.08
More informationAtCor Medical Holdings Limited (ACG)
Volume (million) AtCor Medical Holdings Limited (ACG) 30 March 2015 Speculative Buy Value Creation Ahead Post CPT1 Code Award $0.20 Marcus Hamilton mhamilton@taylorcollison.com.au +61 2 9210 1317 Summary
More informationEclipx Group. Highlights its funding flexibility A$3.77 AUSTRALIA. Event. Impact. Earnings and target price revision.
AUSTRALIA ECX AU Price (at 02:49, 15 Dec 2016 GMT) Outperform A$3.77 Valuation - PER A$ 3.53-3.78 12-month target A$ 4.22 12-month TSR % +16.3 Volatility Index Low/Medium GICS sector Diversified Financials
More informationPlatinum Asset Management
AUSTRALIA PTM AU Price (at 06:10, 11 Jul 2016 GMT) Neutral A$5.52 Valuation A$ - DCF (WACC 9.3%, beta 1.2, ERP 5.0%, RFR 3.3%) 5.19 12-month target A$ 5.36 12-month TSR % +2.6 Volatility Index Low/Medium
More informationCOMPUMEDICS LTD HOLD. CMP Downgrades FY17 Guidance COMPANY UPDATE EVENT KEY TAKE-AWAYS INVESTMENT VIEW
COMPUMEDICS LTD HOLD CMP Downgrades FY17 Guidance Health Care Equipment & Services / Health Care Equipment 7 July 2017 COMPANY UPDATE Ticker CMP Stock Price $0.560 Target Price $0.530 Forecast Capital
More informationWINDLAB LTD HOLD. Lakeland financial close delayed again. Downgrade to HOLD. COMPANY UPDATE EVENT IMPACT INVESTMENT VIEW
WINDLAB LTD HOLD Lakeland financial close delayed again. Downgrade to HOLD. Utilities / Renewable Electricity 7 November 2018 COMPANY UPDATE Ticker WND Stock Price $1.180 Target Price $1.350 Forecast Capital
More informationWisr Ltd (DirectMoney)
Wisr Ltd (DirectMoney) Strategic placement at 56% premium to previous close Wisr Limited (WZR.AX) is an online consumer lending platform competing in the rapidly growing marketplace lending sector. The
More informationIPH Limited ACN Appendix 4D Half Yearly Financial Report Half Year ended 31 December 2016 ( HY17 ) Results for announcement to the market
IPH Limited ACN 169 015 838 Appendix 4D Half Yearly Financial Report Half Year ended 31 December 2016 ( HY17 ) Results for announcement to the market Results Change HY17 $'000 HY16 $'000 Revenue from ordinary
More informationFamily Zone Cyber Safety Limited (FZO) Company Update. Investment Summary. Investment Highlights. Investment Recommendation
BW EQUITIES RESEARCH 14 March 2017 Family Zone Cyber Safety Limited (FZO) Company Update BUY Rating: Target Price 1 : $0.46 Projected Return: 109% 1 12 month target Company Statistics Share Price (A$)
More informationCompany Review 1300SMILES. Corporate Activity Dental Partners. ONT A$6.72 (TP $6.26) Recommendation Hold (no change) Risk Assessment Medium
Ord Minnett Research 2 October 2013 1300SMILES Corporate Activity Dental Partners Event: A consortium led by private equity firm, Archer Capital has recently made an indicative offer for 100% of New Zealand
More informationAspire Mining Ltd (AKM)
4 June 2012 Analyst Stuart Howe 613 9235 1782 Fred Truong 613 9235 1629 Authorisation Jonathan Snape 613 9235 1601 Aspire Mining Ltd (AKM) Ovoot PFS released Recommendation Buy (unchanged) Price $0.13
More informationInsurance Brokers SECTOR REPORT. Solid Hold. -4% Jun-12. Dec-12. Mar-13. Sep-13. Sep-12. Jun-13. Source: APRA, Baillieu Holst estimates
11 May 2018 RECOMMENDATIONS AUB Group (AUB) Rating HOLD Risk Low Price Target $14.50 Share Price $14.17 Steadfast Group (SDF) Rating HOLD Risk Low Price Target $2.80 Share Price $2.88 RESEARCH ANALYST
More informationNoni B (NBL) BUY: FY18e EBITDA +12.8% Key points. Risks and catalysts
Date 09 January 2018 Theme Company Update Company Noni B (NBL) BUY: FY18e EBITDA +12.8% NBL provided a positive 1H18 trading update today, advising LFL sales growth of 3.0% (1.5% in 1H17) and EBITDA of
More informationQBE Insurance. QBE ANZ performance: LMI vs. Excl. LMI (A$m) Source: Company data, Macquarie Research, April 16. Earnings and target price revision
AUSTRALIA QBE AU Price (at 10:44, 27 Apr 2016 GMT) Neutral A$11.19 Valuation A$ - DCF (WACC 9.3%, beta 1.1, ERP 5.0%, RFR 3.8%) 11.34 12-month target A$ 12.00 12-month TSR % +12.7 Volatility Index Low/Medium
More informationWisr Ltd (DirectMoney)
Wisr Ltd (DirectMoney) Interim result draws a line in the sand Wisr Limited (WZR.AX) is an online consumer lending platform competing in the rapidly growing marketplace-lending sector. The company has
More informationSG Fleet Group % growth in FY17. Earnings and target price revision. Price catalyst. Catalyst: Results and contract wins.
AUSTRALIA SGF AU Price (at 07:57, 27 Oct 2016 GMT) Outperform A$3.85 Valuation - PER A$ 3.92-4.18 12-month target A$ 4.37 12-month TSR % +18.1 Volatility Index Medium GICS sector Commercial & Professional
More informationONEVIEW HEALTHCARE PLC
ONEVIEW HEALTHCARE PLC BUY 2017 Result Green Shoots Emerging Health Care Equipment & Services / Health Care Technology 28 February 2018 COMPANY UPDATE Ticker ONE Stock Price $1.900 Target Price $3.04 Forecast
More informationIOOF. Positive flows in 1Q17. FUM and Net Flows for September Qtr Source: Company data, Macquarie Research, Oct 2016.
AUSTRALIA IFL AU Price (at 06:35, 26 Oct 2016 GMT) Outperform A$8.34 Valuation A$ - DCF (WACC 8.8%, beta 1.1, ERP 5.0%, RFR 3.3%) 8.74 12-month target A$ 9.00 12-month TSR % +14.3 Volatility Index Low/Medium
More informationMNF Group Limited (MNF)
MNF Group Limited (MNF) 16 February 2018 Outperform 1H18 Results: Excessive Sell-off Presents Buying Opportunity $5.14 Chris Reindler creindler@taylorcollison.com.au +61 2 9210 1335 Summary (AUD) Market
More informationRegional Express Holdings Ltd REX
20 February 2006 REX $1.15 Analyst Ken Fleming (613) 6224 8511 ken.fleming@tricom.com.au Max Wheeler (613) 6224 9899 Fully diluted shares on issue 115.0M Market cap A$132.3M Performance & Valuation Last
More informationSeek. Progresses Zhaopin privatisation A$16.33 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA SEK AU Price (at 06:33, 07 Apr 2017 GMT) Outperform A$16.33 Valuation - Sum of Parts A$ 16.77 12-month target A$ 16.50 12-month TSR % +3.9 Volatility Index Low/Medium GICS sector Commercial &
More informationCentrale del Latte d'italia
Centrale del Latte d'italia Integration proceeding to plan Q316 results Food & beverages The domestic market remains challenging and beset by deflation, and Centrale del Latte d Italia s (CLI s) flat nine-month
More informationAMP. Earnings and target price revision. No change. Price catalyst. Action and recommendation
AUSTRALIA AU Price (at CLOSE#, 19 Mar 213) Underperform A$5.7 Volatility index Low 12-month target A$ 4.99 12-month TSR % +3.6 Valuation - Sum of Parts A$ 4.68 GICS sector Insurance Market cap A$m 14,855
More informationZip Co. Delivering against expectations. Last Price A$0.86 Target Price A$0.90 (Previously A$0.88) Recommendation Accumulate Risk Higher.
Delivering against expectations Z1P s Mar-18 qtrly report delivered well against our expectations. Positive operating cash flow for the qtr of $1.6m was a +$2.8m improvement qoq, despite the receivables
More informationFisher & Paykel Healthcare
NEW ZEALAND FPH NZ Price (at 05:00, 10 Jul 2015 GMT) Outperform NZ$7.03 Valuation NZ$ 7.39 - DCF (WACC 8.8%, beta 0.9, ERP 7.0%, RFR 4.5%, TGR 2.0%) 12-month target NZ$ 7.80 12-month TSR % +13.1 Volatility
More informationCooks Global Foods. Focused on capital requirements results restated. CGF budgets for 650 stores, targets 800 by 2021
Cooks Global Foods Focused on capital requirements Company update Food & beverages Cooks Global Foods (CGF) has reaffirmed its 650-store budget for Esquires Coffee by March 2021, but has acknowledged that
More informationFor personal use only
ASX Announcement 20 November 2015 AGM Presentations In accordance with the ASX Listing Rules and the Corporations Act 2001, attached are the presentations to be given at today s Annual General Meeting.
More informationXenith IP Group Limited
Xenith IP Group Limited Results Financial Year to 30 June 2017 29 August 2017 Craig Dower Stuart Smith Lesley Kennedy CEO and Managing Director Executive Director and Head of Corporate Development CFO
More informationAberdeen Asset Management
Aberdeen Asset Management Double-digit growth at a reasonable price Institutional update Investment companies In line with the sell-off in emerging markets, Aberdeen s share price has fallen c 20% since
More informationCardno. Tough half over A$2.88 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA CDD AU Price (at 04:53, 17 Feb 2015 GMT) Neutral A$2.88 Valuation - Sum of Parts A$ 2.80-3.43 12-month target A$ 3.12 12-month TSR % +18.4 Volatility Index Medium GICS sector Capital Goods Market
More informationMotorCycle Holdings (MTO) New HOLD: Harley still lacking traction. Key points. Risks and catalysts
Date Theme Company Update Company MotorCycle Holdings (MTO) New HOLD: Harley still lacking traction We moderate to HOLD (from Buy) with a revised target of $2.36 p/share. We were previously encouraged
More informationBharat Forge. Result Update. Q4FY13 Result Highlights. Valuation. No Respite in Sight May 29, Institutional Research 1
[ Result Update Equity India Forging & Industrials Bharat Forge Ltd. No Respite in Sight May 29, 2013 CMP (`) Target (`) 241 238 Potential Upside Absolute Rating (1.24)% HOLD Market Info (as on May 28,
More informationZip Co. Improved medium term cost guidance. Last Price A$0.96 Target Price A$1.00 (Previously A$0.90) Recommendation Accumulate Risk Higher
Improved medium term cost guidance Z1P s Jun-18 qtrly update outlined a beat against our cash flow expectations, with the company having generated positive operating cash flow (after bad debts) for the
More informationSims Metal Management
AUSTRALIA SGM AU Price (at 5:11, 17 Nov 215 GMT) Outperform A$7.19 Valuation - EV/EBIT A$ 8.49-9.6 12-month target A$ 8.9 12-month TSR % +26.6 Volatility Index Medium GICS sector Materials Market cap A$m
More informationFairfax / REA Group. No housing boom here. A$0.81 Valuation A$ Sum of Parts 12-month target A$ month TSR % +16.0
AUSTRALIA FXJ AU Price (at 05:11, 03 Nov 2016 GMT) Outperform A$0.81 Valuation A$ 0.88 - Sum of Parts 12-month target A$ 0.90 12-month TSR % +16.0 Volatility Index Low/Medium Market cap A$m 1,863 30-day
More informationAustralian Banks. Funding markets open for now
AUSTRALIA Weekly performance 4% 2% % -2% -4% -6% -8% -1% Source: IRESS, August 212 Rolling monthly performance 8% 6% 4% 2% % -2% -4% -6% Source: IRESS, August 212 Rolling yearly performance % 15% 5% -5%
More information